92 related articles for article (PubMed ID: 21252284)
1. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.
Liu L; Shi H; Liu Y; Anderson A; Peterson J; Greger J; Martin AM; Gilmer TM
Mol Cancer Ther; 2011 Mar; 10(3):518-30. PubMed ID: 21252284
[TBL] [Abstract][Full Text] [Related]
2. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
3. Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells.
Sato Y; Yashiro M; Takakura N
Cancer Sci; 2013 Dec; 104(12):1618-25. PubMed ID: 24112719
[TBL] [Abstract][Full Text] [Related]
4. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
Huang C; Park CC; Hilsenbeck SG; Ward R; Rimawi MF; Wang YC; Shou J; Bissell MJ; Osborne CK; Schiff R
Breast Cancer Res; 2011 Aug; 13(4):R84. PubMed ID: 21884573
[TBL] [Abstract][Full Text] [Related]
5. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Choueiri TK; Vaishampayan U; Rosenberg JE; Logan TF; Harzstark AL; Bukowski RM; Rini BI; Srinivas S; Stein MN; Adams LM; Ottesen LH; Laubscher KH; Sherman L; McDermott DF; Haas NB; Flaherty KT; Ross R; Eisenberg P; Meltzer PS; Merino MJ; Bottaro DP; Linehan WM; Srinivasan R
J Clin Oncol; 2013 Jan; 31(2):181-6. PubMed ID: 23213094
[TBL] [Abstract][Full Text] [Related]
6. Interaction between Her2 and Beclin-1 proteins underlies a new mechanism of reciprocal regulation.
Han J; Hou W; Lu C; Goldstein LA; Stolz DB; Watkins SC; Rabinowich H
J Biol Chem; 2013 Jul; 288(28):20315-25. PubMed ID: 23703612
[TBL] [Abstract][Full Text] [Related]
7. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
Rexer BN; Ham AJ; Rinehart C; Hill S; Granja-Ingram Nde M; González-Angulo AM; Mills GB; Dave B; Chang JC; Liebler DC; Arteaga CL
Oncogene; 2011 Oct; 30(40):4163-74. PubMed ID: 21499296
[TBL] [Abstract][Full Text] [Related]
8. Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.
Forde PM; Kelly RJ
Oncologist; 2013; 18(7):823-32. PubMed ID: 23853247
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
Reddy TP; Choi DS; Anselme AC; Qian W; Chen W; Lantto J; Horak ID; Kragh M; Chang JC; Rosato RR
Breast Cancer Res; 2020 May; 22(1):48. PubMed ID: 32414394
[TBL] [Abstract][Full Text] [Related]
10. Resistance to targeted cancer drugs through hepatocyte growth factor signaling.
Heynen GJ; Fonfara A; Bernards R
Cell Cycle; 2014; 13(24):3808-17. PubMed ID: 25426675
[TBL] [Abstract][Full Text] [Related]
11. Two dimensions in targeting HER2.
Moasser MM
J Clin Oncol; 2014 Jul; 32(19):2074-7. PubMed ID: 24868026
[No Abstract] [Full Text] [Related]
12. HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
Martinho O; Silva-Oliveira R; Cury FP; Barbosa AM; Granja S; Evangelista AF; Marques F; Miranda-Gonçalves V; Cardoso-Carneiro D; de Paula FE; Zanon M; Scapulatempo-Neto C; Moreira MA; Baltazar F; Longatto-Filho A; Reis RM
Theranostics; 2017; 7(3):717-732. PubMed ID: 28255362
[TBL] [Abstract][Full Text] [Related]
13. HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.
Alexis F; Basto P; Levy-Nissenbaum E; Radovic-Moreno AF; Zhang L; Pridgen E; Wang AZ; Marein SL; Westerhof K; Molnar LK; Farokhzad OC
ChemMedChem; 2008 Dec; 3(12):1839-43. PubMed ID: 19012296
[TBL] [Abstract][Full Text] [Related]
14. Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met.
Chen GZ; Dai WS; Zhu HC; Song HM; Yang X; Wang YD; Min H; Lu Q; Liu S; Sun XC; Zeng XN
J Cancer; 2017; 8(6):983-992. PubMed ID: 28529610
[TBL] [Abstract][Full Text] [Related]
15. An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics.
Benvenuti S; Gentile A; Lazzari L; Arnesano A; Trusolino L; Comoglio PM
Mol Oncol; 2014 Mar; 8(2):378-88. PubMed ID: 24389243
[TBL] [Abstract][Full Text] [Related]
16.
El Darsa H; El Sayed R; Abdel-Rahman O
J Exp Pharmacol; 2020; 12():349-361. PubMed ID: 33116950
[TBL] [Abstract][Full Text] [Related]
17. Differential Pattern of Resistance and Sensitivity to Different Classes of MET Inhibitors for
Piper-Vallillo AJ; Kobayashi SS; Costa DB
JTO Clin Res Rep; 2021 Mar; 2(3):100133. PubMed ID: 34589996
[No Abstract] [Full Text] [Related]
18. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.
Arcila ME; Nafa K; Chaft JE; Rekhtman N; Lau C; Reva BA; Zakowski MF; Kris MG; Ladanyi M
Mol Cancer Ther; 2013 Feb; 12(2):220-9. PubMed ID: 23371856
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
[TBL] [Abstract][Full Text] [Related]
20. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met.
Stabile LP; He G; Lui VW; Thomas S; Henry C; Gubish CT; Joyce S; Quesnelle KM; Siegfried JM; Grandis JR
Clin Cancer Res; 2013 Jan; 19(2):380-92. PubMed ID: 23213056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
